Cover Image
市場調查報告書

搔癢:開發平台分析

Pruritus - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213132
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
搔癢:開發平台分析 Pruritus - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 123 Pages
簡介

所謂搔癢是指癢造成的不舒適感,有皮膚發紅、腫、斑點、水腫、乾燥、龜裂、皮革化、鱗狀化等症狀。風險係數有溫度和過敏、氣喘、花粉症、蕁麻疹、皮膚炎等,治療方法有服用皮質類固醇劑、抗組織胺藥、抗憂鬱劑等。

本報告涵括全球搔癢治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

搔癢概要

治療藥的開發

  • 搔癢開發中產品:概要
  • 搔癢開發中產品:比較分析

搔癢:開發中的治療藥:各企業

搔癢:開發中的治療藥:大學·研究機關別

搔癢:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

搔癢:開發中的產品:各企業

搔癢:開發中的產品:大學·研究機關別

搔癢:治療藥的開發企業

  • AlbireoPharma
  • Amorepacific Corporation
  • Cara Therapeutics, Inc.
  • 中外製藥
  • Creabilis SA
  • ELORAC, Inc.
  • Faes Farma, SA
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • NeRRe Therapeutics Ltd
  • 日本新藥
  • Patara Pharma, Inc.
  • Phosphagenics Limited
  • RDD Pharma Ltd.
  • 三和化學研究所
  • 鹽野義製藥
  • 大日本住友製藥
  • Tioga Pharmaceuticals, Inc.
  • Trevi Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.

搔癢:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • >A-4250
    • 產品概要
    • 作用機制
    • R&D的進展
  • aprepitant
  • asimadoline
  • ASN-008
  • bilastine
  • C-745
  • CR-845
  • cromolyn sodium
  • CT-327
  • CT-340
  • desloratadine
  • GSK-2330672
  • lidocaine hydrochloride
  • nalbuphine hydrochloride ER
  • naloxone hydrochloride
  • nemolizumab
  • NS-141
  • orvepitant maleate
  • PAC-14028
  • Peptides to Target TRPV1 for Pain and Itch
  • RDD-1609
  • serlopitant
  • SK-1405
  • Small Molecule to Agonize CB2 for Pruritus
  • Small Molecule to Inhibit Substance P for Pruritus
  • Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis
  • Small Molecules to Block NaV1.7 Channel for Pain and Pruritus
  • Small Molecules to Inhibit Mas-Related G-Protein Coupled Receptor for Pruritus
  • tradipitant

最新的開發平台趨勢

暫停中的計劃

中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8405IDB

Summary

Global Markets Direct's, 'Pruritus - Pipeline Review, H2 2016', provides an overview of the Pruritus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pruritus
  • The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
  • The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pruritus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pruritus Overview
  • Therapeutics Development
    • Pipeline Products for Pruritus - Overview
    • Pipeline Products for Pruritus - Comparative Analysis
  • Pruritus - Therapeutics under Development by Companies
  • Pruritus - Therapeutics under Investigation by Universities/Institutes
  • Pruritus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pruritus - Products under Development by Companies
  • Pruritus - Products under Investigation by Universities/Institutes
  • Pruritus - Companies Involved in Therapeutics Development
    • Albireo AB
    • Alveonix AG
    • Amorepacific Corporation
    • Asana BioSciences, LLC
    • Cara Therapeutics, Inc.
    • Chugai Pharmaceutical Co., Ltd.
    • Creabilis SA
    • ELORAC, Inc.
    • Faes Farma, S.A.
    • GlaxoSmithKline Plc
    • Hydra Biosciences, Inc.
    • LEO Pharma A/S
    • Merck & Co., Inc.
    • NeRRe Therapeutics Ltd
    • Nippon Shinyaku Co., Ltd.
    • Patara Pharma, Inc.
    • Phosphagenics Limited
    • RDD Pharma Ltd.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
    • Shionogi & Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Teikoku Pharma USA, Inc.
    • Tioga Pharmaceuticals, Inc.
    • Trevi Therapeutics, Inc.
    • Vanda Pharmaceuticals Inc.
  • Pruritus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • asimadoline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ax-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ax-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cromolyn sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-327 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • desloratadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • difelikefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nalbuphine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nemolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orvepitant maleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDD-1609 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serlopitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize CB2 for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Substance P for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tradipitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pruritus - Dormant Projects
  • Pruritus - Discontinued Products
  • Pruritus - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings
      • Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting
      • Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
      • Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain
      • Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
      • May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845
      • Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
      • Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board
      • Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis
      • Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration
      • Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
      • Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus
      • Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
      • Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting
      • Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pruritus, H2 2016
  • Number of Products under Development for Pruritus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pruritus - Pipeline by Albireo AB, H2 2016
  • Pruritus - Pipeline by Alveonix AG, H2 2016
  • Pruritus - Pipeline by Amorepacific Corporation, H2 2016
  • Pruritus - Pipeline by Asana BioSciences, LLC, H2 2016
  • Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Pruritus - Pipeline by Creabilis SA, H2 2016
  • Pruritus - Pipeline by ELORAC, Inc., H2 2016
  • Pruritus - Pipeline by Faes Farma, S.A., H2 2016
  • Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Pruritus - Pipeline by LEO Pharma A/S, H2 2016
  • Pruritus - Pipeline by Merck & Co., Inc., H2 2016
  • Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2016
  • Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Pruritus - Pipeline by Patara Pharma, Inc., H2 2016
  • Pruritus - Pipeline by Phosphagenics Limited, H2 2016
  • Pruritus - Pipeline by RDD Pharma Ltd., H2 2016
  • Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
  • Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Pruritus - Pipeline by Teikoku Pharma USA, Inc., H2 2016
  • Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016
  • Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2016
  • Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pruritus - Dormant Projects, H2 2016
  • Pruritus - Dormant Projects (Contd..1), H2 2016
  • Pruritus - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pruritus, H2 2016
  • Number of Products under Development for Pruritus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top